Nottingham, UK – Sygnature Chemical Services, a leading provider of medicinal chemistry, synthetic chemistry and chemical library services, is pleased to announce the appointment of Dr. Paul Clewlow as senior vice-president for business development, and as an executive member of the board of directors.
Dr Simon Hirst, chief executive officer of Sygnature CS commented, “Paul is a great addition to Sygnature’s senior management team. He has over 20 years’ experience in business development through his involvement with pharmaceutical companies and CROs, and will be invaluable in helping us to chart the future direction of Sygnature CS. Paul joins the company at exciting time in our evolution. Sales have doubled over the past year and we have recruited experienced chemists to occupy the £1m expansion of our research facility. The prospects for further growth are excellent and I am sure Paul will make a significant contribution to the success of Sygnature’s business.”
Dr Paul Clewlow added, “I am delighted to join Sygnature CS at a time when the company is well placed to take advantage of the increasing opportunities presented to it by the pharmaceutical industry. Drug discovery and development is an expensive and time-consuming process, the chances of successfully producing a new marketed drug remain small, and the industry is going through an unprecedented period of change and uncertainty. In the face of these challenges, companies undertaking pharmaceutical R&D require, more than ever, a trusted strategic CRO partner, with significant industry experience to increase the value of their drug discovery programmes, and accelerate them into development. I believe that Sygnature CS is that trusted partner, and I am looking forward to working with Simon and his colleagues.”